Physician profile
Charles Duss
NPI 1043356538
$6,920.38
in general payments reported to CMS, 2019-2025
33 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $724 · 2021: $1,548 · 2022: $1,186 · 2023: $276 · 2024: $1,220 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.89 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,712.54 | 2019-2025 | Clareon Panoptix Pro, Clareon, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $611.50 | 2020-2025 | Cequa |
| Horizon Therapeutics Plc | $548.81 | 2020-2023 | Uplizna, Tepezza |
| Allergan, INC. | $512.49 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $481.20 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $395.08 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $319.80 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $313.45 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $306.28 | 2019-2021 | |
| Rxsight INC | $191.05 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $165.76 | 2021 | |
| Oyster Point Pharma, INC. | $163.55 | 2024-2025 | Tyrvaya |
| Glaukos Corporation | $155.22 | 2025 | Idosetr |
| Novartis Pharmaceuticals Corporation | $137.11 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $133.85 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $112.25 | 2019 | |
| Abbvie INC. | $108.78 | 2022-2025 | Lumigan |
| Harrow Eye, LLC | $98.10 | 2024-2025 | Vevye, Iheezo |
| Rayner Intraocular Lenses Limited | $94.95 | 2022-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Amgen INC. | $48.33 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $47.72 | 2022 | |
| Sandoz INC. | $39.32 | 2024 | Cimerli |
| Dompe US, INC. | $37.66 | 2021-2023 | Oxervate |
| Coherus Oncology, INC. | $30.72 | 2022 | |
| Biotissue Holdings INC. | $28.05 | 2021-2024 | |
| Ocular Therapeutix, INC. | $23.66 | 2024 | Dextenza |
| Johnson & Johnson Vision Care, INC. | $21.85 | 2024 | |
| Apellis Pharmaceuticals, INC. | $19.32 | 2022 | |
| Eyepoint US, INC. | $16.22 | 2021 | |
| Sight Sciences, INC. | $14.41 | 2022 | |
| Shire North American Group INC | $13.83 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.39 | 2019 | |
| New World Medical,INC. | $4.13 | 2022-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Clearpath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Duss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.